NEA Management Company as of March 31, 2026
Portfolio Holdings for NEA Management Company
NEA Management Company holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Arcellx Common Stock (ACLX) | 19.9 | $350M | 3.0M | 114.82 | |
| Celcuity (CELC) | 14.8 | $261M | 2.3M | 114.14 | |
| Spyglass Pharma Com Shs | 10.9 | $192M | 7.4M | 25.91 | |
| Trevi Therapeutics (TRVI) | 9.0 | $158M | 13M | 11.93 | |
| Savara (SVRA) | 7.6 | $134M | 25M | 5.46 | |
| Monte Rosa Therapeutics (GLUE) | 7.2 | $127M | 7.7M | 16.45 | |
| Mbx Biosciences (MBX) | 6.1 | $108M | 3.6M | 29.85 | |
| Zenas Biopharma (ZBIO) | 4.5 | $79M | 4.0M | 19.55 | |
| Coursera (COUR) | 4.3 | $75M | 13M | 5.82 | |
| Aurinia Pharmaceuticals (AUPH) | 3.3 | $59M | 4.0M | 14.82 | |
| Oric Pharmaceuticals (ORIC) | 3.0 | $52M | 4.1M | 12.67 | |
| CRISPR Therapeutics Namen Akt (CRSP) | 2.9 | $50M | 1.1M | 47.57 | |
| Phathom Pharmaceuticals (PHAT) | 1.2 | $22M | 2.0M | 11.11 | |
| CVRX (CVRX) | 1.1 | $19M | 2.0M | 9.46 | |
| Korro Bio (KRRO) | 0.8 | $15M | 1.3M | 11.32 | |
| X4 Pharmaceuticals | 0.8 | $13M | 3.2M | 4.13 | |
| Champions Oncology Com New (CSBR) | 0.6 | $9.9M | 1.7M | 5.75 | |
| Black Diamond Therapeutics (BDTX) | 0.5 | $9.5M | 4.4M | 2.13 | |
| Inventiva SA Ads (IVA) | 0.5 | $8.0M | 1.5M | 5.49 | |
| Nkarta (NKTX) | 0.4 | $7.5M | 3.6M | 2.11 | |
| Athira Pharma (LONA) | 0.3 | $4.8M | 464k | 10.28 | |
| Senti Biosciences Com New (SNTI) | 0.2 | $3.1M | 3.8M | 0.81 | |
| Marker Therapeutics Com New (MRKR) | 0.1 | $2.1M | 1.6M | 1.30 | |
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $2.0M | 479k | 4.14 | |
| Gossamer Bio (GOSS) | 0.0 | $329k | 1.0M | 0.33 | |
| Imagenebio (IMA) | 0.0 | $250k | 50k | 5.00 |
